| Business Summary | | Zonagen,
Incorporated
is
a
development
stage
biopharmaceutical
company
engaged
in
the
development
of
products
for
the
reproductive
system,
including
sexual
dysfunction,
vaccine
adjuvants,
products
for
fertility
and
female
health,
as
well
as
urological
applications,
specifically
prostate
cancer.
Zonagen's
lead
product,
Vasomax,
is
a
rapidly
disintegrating
oral
formulation
of
phentolamine
for
the
treatment
of
male
erectile
dysfunction
(MED).
Vasofem
is
being
developed
by
the
Company
to
treat
female
sexual
dysfunction.
Zonagen
is
developing
a
new
class
of
compounds,
the
initial
focus
of
which
will
be
endometriosis
and
uterine
fibroids.
The
Company
is
developing
two
therapeutic
vaccine
products
to
prevent
contraception
by
stimulating
an
immune
response. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Zonagen,
Inc.
is
development
stage
biopharmaceutical
company
engaged
in
the
development
of
pharmaceutical
products
for
the
reproductive
system,
including
sexual
dysfunction,
urology,
contraception
and
infertility.
For
the
six
months
ended
6/30/01,
total
revenues
fell
3%
to
$2.1
million.
Net
loss
before
acct.
change
fell
87%
to
$254
thousand.
Results
reflect
increased
revenue
from
SBIR
grants
and
lower
R&D
expenses
due
to
a
cost
reduction
program. | More
from
Market Guide: Significant
Developments |
| | | Martin
P. Sutter,
Chmn. Joseph
S. Podolski,
Pres./CEO Paul
Lammers,
Sr. VP. | More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|